GSK
GSK plc
There isn't enough reported data to score GSK yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
GSK Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Healthy |
GSK's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
GSK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.7x | $16.03 | -68% |
| Fair | 14x | $25.09 | -50% |
| Current | 14x | $50.64 | — |
| Expensive | 16x | $29.98 | -41% |
Historical ranges are pointers, not guarantees.
GSK's PE is 14x, but its earnings don't support one, so it isn't a reliable read right now.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over GSK in the historical PE scenario, which offers more potential upside but is not a forecast.
GSK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for GSK, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
GSK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $1.85 | +123% |
| Q4 2024 | $0.83 | -48% |
| Q4 2023 | $1.59 | -67% |
| Q4 2022 | $4.87 | +238% |
| Q4 2021 | $1.44 | -24% |
| Q4 2020 | $1.90 | +23% |
| Q4 2019 | $1.54 | +27% |
| Q4 2018 | $1.21 | +133% |
GSK earned $1.85 per share over the past year, up 28% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over GSK in the latest year-over-year earnings comparison.
GSK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $43.5B | +4.1% |
| Q4 2024 | $41.7B | +3.5% |
| Q4 2023 | $40.3B | +3.4% |
| Q4 2022 | $39B | -14% |
| Q4 2021 | $45.4B | 0% |
| Q4 2020 | $45.4B | +1% |
| Q4 2019 | $44.9B | +9.5% |
| Q4 2018 | $41B | +2.1% |
GSK's revenue is shrinking: $43.5B last quarter, down 4.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 24% | +6.1 points |
| Q4 2024 | 13% | -10 points |
| Q4 2023 | 22% | +1.6 points |
| Q4 2022 | 22% | +4.2 points |
| Q4 2021 | 18% | +4.6 points |
| Q4 2020 | 23% | +15 points |
| Q4 2019 | 21% | +1.7 points |
| Q4 2018 | 18% | N/A |
GSK's operating margin was 24% last quarter, up 6.1 points from the same quarter a year ago, near the top of its range since 2016.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over GSK in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
GSK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $8.5B | +24% |
| Q4 2024 | $6.9B | -5.5% |
| Q4 2023 | $7.3B | -13% |
| Q4 2022 | $8.3B | -7.7% |
| Q4 2021 | $9B | -6% |
| Q4 2020 | $9.6B | +6.8% |
| Q4 2019 | $9B | -4.5% |
| Q4 2018 | $9.4B | +32% |
GSK's free cash flow has been positive every quarter since mid-2016: $30.9B over the past year, down 16% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
GSK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -25M shares |
| 1 year | +1.6% | +65M shares |
| 3 years | +110% | +2.2B shares |
GSK has 4.1B diluted shares, up 1.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $1.8B |
| Q4 2016 | $5.3M |
| Q3 2016 | $16M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over GSK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
GSK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 1.5x | Healthy |
| Q4 2024 | 2.0x | Moderate |
| Q4 2023 | 1.8x | Healthy |
| Q4 2022 | 2.2x | Moderate |
| Q4 2021 | 2.4x | Moderate |
| Q4 2020 | 2.1x | Moderate |
| Q4 2019 | 3.2x | Elevated |
| Q4 2018 | 3.1x | Elevated |
GSK's net debt is about 1.5 years of its operating earnings (EBITDA), down from 2.4 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
GSK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.6 | Neutral |
| Stochastic | 55.5 | Neutral |
GSK's weekly RSI is 51 (neutral) and its Stochastic is 56 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
GSK PE vs Healthcare Sector
| Metric | GSK | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 47% below |
| PE % | 53 | 29 | 24 pts above |
GSK has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
GSK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $49.2 | 2.9% above |
| 20 week MA | $50.4 | 0.4% above |
| 50 week MA | $51.9 | 2.4% below |
| 100 week MA | $45.5 | 11% above |
| 200 week MA | $41.7 | 21% above |
GSK's trend is mixed: it's above four of its five weekly moving averages, and 21% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over GSK on trend strength, trading above more of its moving averages.
GSK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $47.3 | $36.1 | -24% |
| 2021 | $36.1 | $43.8 | +21% |
| 2022 | $43.8 | $35.2 | -20% |
| 2023 | $35.2 | $37.1 | +5.2% |
| 2024 | $37.1 | $34.1 | -8% |
| 2025 | $34.1 | $49.1 | +44% |
| 2026 YTD | $49.1 | $50.6 | +3.2% |
GSK has finished lower in three of the last six years. It's up 3.2% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over GSK on returns for 2026, with the stronger performance.